糖尿病肾脏病风险分层干预的健康经济学评价
研究基于新加坡糖尿病队列(N=9660)构建多状态马尔可夫模型,模拟多族裔亚洲人群糖尿病肾脏病(DKD)进展,并在全国行政数据集(N=73,256)中验证。从医疗系统视角评估钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)假设性干预的成本效果与预算影响。结果显示SGLT2i干预在低风险(G0-G2)2型糖尿病人群中具有成本效果,而在高风险(G3-G4)人群中无成本效果。
要点
- 每年53.0-88.8%的参与者维持同一DKD分期,进展或回退至下一分期的概率在G0与G1之间最高。
- SGLT2i干预在低风险(G0-G2)2型糖尿病人群中短期和长期均具有成本效果。
- SGLT2i干预在高风险(G3-G4)2型糖尿病人群中短期和长期均无成本效果。
核心结论
- 研究基于真实世界数据构建了稳健的DKD进展模型,并通过对已知有效性干预进行风险分层经济建模展示了其价值。
- 该模型可帮助政策制定者和卫生专业人员评估人群层面干预,以支持循证政策决策。
研究设计与样本
- 使用新加坡糖尿病队列(N=9660)构建多状态马尔可夫模型,依据KDIGO指南推导慢性肾脏病(CKD)分期特异性疾病进展转移概率。
- 模型在50%训练集和50%测试集中进行内部验证,并在全国行政数据集(N=73,256)中进一步验证。
- 从医疗系统视角,对不同时间范围内、基于eGFR定义的DKD风险分层的低风险(G0-G2)和高风险(G3-G4)人群,进行SGLT2i假设性干预的成本效果与预算影响分析。
主要发现
- 每年超过一半的参与者(53.0-88.8%)维持在同一DKD分期。
- 进展或回退至下一DKD分期的概率在G0与G1之间最高。
- SGLT2i干预在低风险2型糖尿病人群中短期和长期均具有成本效果,但在高风险2型糖尿病人群中短期和长期均无成本效果。
- 假设市场 uptake 每年增加5%,实施SGLT2i干预将导致5年累计成本增加41.5%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: The study aimed to model the progression of diabetic kidney disease (DKD) in a multi-ethnic Asian population and evaluate the economic impact of a risk-stratified intervention for DKD management. METHODS: Using the Singapore Diabetic Cohort (N=9660), multi-state Markov models were constructed to derive chronic kidney disease (CKD) stage-specific transition probabilities for disease progression based on Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. These were internally validated in 50% training and 50% testing datasets and further validated in national administrative datasets (N=73,256). A cost-effectiveness and budget impact analysis for a hypothetical intervention of sodium-glucose cotransporter 2 inhibitors (SGLT2is) was conducted from a healthcare system perspective, across different time horizons, in low-risk (G0-G2) and high-risk individuals (G3-G4) based on eGFR-defined DKD risk stages. RESULTS: Annually, more than half of the participants (53.0-88.8%) stayed in the same DKD stage, with the probabilities of progressing or regressing to the next DKD stage being highest between stages G0 and G1. The SGLT2i intervention was cost-effective when given in low-risk, but not in high-risk, individuals with type 2 diabetes in both the short and the long term. Additionally, implementing the SGLT2i intervention would incur a 5 year cumulative cost increase of 41.5%, assuming an annual 5% increase in market uptake. CONCLUSIONS/INTERPRETATION: We developed a robust model of DKD progression based on real-world data and demonstrated its value through economic modelling of risk-stratified interventions with known effectiveness. This model can aid policymakers and health professionals in evaluating population-level interventions for evidence-based policy decisions.
引用
- Kalhan TA, Luo M, Chai JH, et al. Health economic evaluation of a risk-stratified intervention in diabetic kidney disease. Diabetologia. 2025. PMID: 40739365. doi:10.1007/s00125-025-06498-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。